<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262119</url>
  </required_header>
  <id_info>
    <org_study_id>MNV-20-171005</org_study_id>
    <nct_id>NCT00262119</nct_id>
  </id_info>
  <brief_title>MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure</brief_title>
  <official_title>MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <brief_summary>
    <textblock>
      The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and
      atrial preventive and antitachycardia pacing therapies on the reduction of a composite
      clinical outcome composed of any death, permanent atrial fibrillation, and cardiovascular
      hospitalizations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kristensen et al. reported that AAIR pacing reduces atrial fibrillation (AF) development
      compared to DDDR pacing in sinus node disfunction patients.

      Several authors have shown that, in patients with intact AV conduction, unnecessary chronic
      RV pacing can cause detrimental effects such as AF, left ventricular (LV) dysfunction and
      congestive heart failure. These findings arose the hypothesis that the non-physiologic nature
      of ventricular pacing may result in electrophysiological and LV remodeling changes that have
      potentially deleterious long-term effects.

      The MVP mode, present in the Medtronic pacemaker EnRhythm, provides atrial based pacing with
      ventricular backup. It operates in true AAI(R) mode, it provides ventricular backup in case
      of a single conduction loss and converts to DDD(R) mode in case of persistent loss of AV
      conduction.

      Aim of this study is to test the impact of the MVP pacing mode and atrial preventive and
      antitachycardia pacing therapies on the reduction of a composite clinical outcome composed by
      any death, permanent AF, cardiovascular hospitalizations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>The outcome measurement is the 2 years incidence, calculated by Kaplan Meier survival analysis, of the composite endpoint composed by death for any cause, cardiovascular hospitalization or permanent AF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death for All Causes at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence, estimated via Kaplan Meier survival analysis, of death for any cause at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Permanent Atrial Fibrillation at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence, estimated via Kaplan Meier survival analysis, of permanent atrial fibrillation at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiovascular Hospitalizations at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence, estimated via Kaplan Meier survival analysis, of cardiovascular hospitalizations at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of Composite Clinical Endpoint</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Symptoms</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Medications</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percentage of Ventricular Pacing</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Hospitalization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent Atrial Fibrillation (AF)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Atrioventricular (AV) Block and Pacemaker Dependency</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of Stroke, Transient Ischemic Attack (TIA) and Arterial Embolism</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram Data About Left Ventricular Fractional Shortening and Ejection Fraction and Left Atrium Dilatation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in All the Patients With MVP ON Between Patients With Optimized AV-delay and Patients Without Optimized AV-delay</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Development of the Composite Endpoint Between All Randomized Subjects in the Three Arms in Subgroups of Patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, Type, and Associated Cost of Health Care Utilization and Utility</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1300</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PM programming according to actual clinical practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVP Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PM programming according to actual clinical practice + MVP algorithm ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDDRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker Medtronic EnRhythm</intervention_name>
    <description>Pacemaker specific programming</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>MVP Only</arm_group_label>
    <arm_group_label>DDDRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Class I/Class II indications for dual chamber pacing

          -  Previous implant of an EnRhythm dual chamber implantable pulse generator (IPG) since
             maximum 2 weeks

          -  History of atrial arrhythmias (at least one electrocardiogram [ECG] or Holter
             documented episodes in the last 12 months)

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Pregnancy

          -  Unwilling or unable to give informed consent or to commit to follow-up schedule

          -  Medical conditions that preclude protocol required testing or limit study
             participation

          -  Enrolled or intend to participate in another clinical trial during the course of this
             study

          -  A life expectancy of less than 2 years

          -  Patient is a candidate for an implantable cardioverter defibrillator (ICD) or cardiac
             resynchronization therapy (CRT) device implant

          -  Anticipated major cardiac surgery within the course of this study

          -  Permanent III degree AV-block or history of AV node ablation

          -  History of permanent AF (as defined below)

          -  AF ablation (left pulmonary veins) or other cardiac surgery &lt; 3 months

          -  Prior implant of defibrillator device or pacemaker (apart from EnRhythm IPG implanted
             within two weeks)

          -  Uncontrolled hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Padeletti, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Careggi - Firenze</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Boriani, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Sant'Orsola - Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Mont, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard C Funck, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philipps University Hospital - Marburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carsten W Israel, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>J. W. Goethe University Hospital - Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Pürerfellner, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabethinen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonis S Manolis, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evagelismos Hospital - Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Pisapia, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Joseph - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Tukkie, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennemer Gasthuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Italia S.p.A.</name>
      <address>
        <city>Rome</city>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000 May 11;342(19):1385-91.</citation>
    <PMID>10805823</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L; Mode Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002 Jun 13;346(24):1854-62.</citation>
    <PMID>12063369</PMID>
  </reference>
  <reference>
    <citation>Mattioli AV, Vivoli D, Mattioli G. Influence of pacing modalities on the incidence of atrial fibrillation in patients without prior atrial fibrillation. A prospective study. Eur Heart J. 1998 Feb;19(2):282-6.</citation>
    <PMID>9519322</PMID>
  </reference>
  <reference>
    <citation>Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997 Oct 25;350(9086):1210-6.</citation>
    <PMID>9652562</PMID>
  </reference>
  <reference>
    <citation>Kristensen L, Nielsen JC, Mortensen PT, Pedersen OL, Pedersen AK, Andersen HR. Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome. Heart. 2004 Jun;90(6):661-6.</citation>
    <PMID>15145874</PMID>
  </reference>
  <reference>
    <citation>Nielsen JC, Andersen HR, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation. 1998 Mar 17;97(10):987-95.</citation>
    <PMID>9529267</PMID>
  </reference>
  <reference>
    <citation>Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol. 2003 Aug 20;42(4):614-23.</citation>
    <PMID>12932590</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2005</study_first_submitted>
  <study_first_submitted_qc>December 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>May 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physiological pacing</keyword>
  <keyword>Antitachycardia pacing therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was between February 2006 and April 2010. Patients were enrolled in cardiology departments.</recruitment_details>
      <pre_assignment_details>A total of 1300 patients were enrolled in the study. Enrollment was followed by a 1-month run-in period. Patients with ventricular pacing ≥ 95% on device check in the run-in period were excluded from the study. At the end of the run-in period, randomization was performed. In all, 1166 patients were randomized and followed up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="P2">
          <title>MVP Only</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="P3">
          <title>DDDRP</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="398"/>
                <participants group_id="P3" count="383"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="B2">
          <title>MVP Only</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="B3">
          <title>DDDRP</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="385"/>
            <count group_id="B2" value="398"/>
            <count group_id="B3" value="383"/>
            <count group_id="B4" value="1166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="9"/>
                    <measurement group_id="B2" value="74" spread="9"/>
                    <measurement group_id="B3" value="74" spread="9"/>
                    <measurement group_id="B4" value="74" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kuwait</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Death for All Causes at 2 Years</title>
        <description>Incidence, estimated via Kaplan Meier survival analysis, of death for any cause at 2 years</description>
        <time_frame>2 years</time_frame>
        <population>The analysis was intention to treat therefore all randomized patients were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O2">
            <title>MVP Only</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O3">
            <title>DDDRP</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
        </group_list>
        <measure>
          <title>Death for All Causes at 2 Years</title>
          <description>Incidence, estimated via Kaplan Meier survival analysis, of death for any cause at 2 years</description>
          <population>The analysis was intention to treat therefore all randomized patients were included in the analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.6" upper_limit="8.5"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.3" upper_limit="7.9"/>
                    <measurement group_id="O3" value="4.6" lower_limit="2.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Permanent Atrial Fibrillation at 2 Years</title>
        <description>Incidence, estimated via Kaplan Meier survival analysis, of permanent atrial fibrillation at 2 years</description>
        <time_frame>2 years</time_frame>
        <population>The analysis was intention to treat therefore all randomized patients were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O2">
            <title>MVP Only</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O3">
            <title>DDDRP</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Permanent Atrial Fibrillation at 2 Years</title>
          <description>Incidence, estimated via Kaplan Meier survival analysis, of permanent atrial fibrillation at 2 years</description>
          <population>The analysis was intention to treat therefore all randomized patients were analysed</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="6.6" upper_limit="12.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="5.3" upper_limit="11.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="2.2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cardiovascular Hospitalizations at 2 Years</title>
        <description>Incidence, estimated via Kaplan Meier survival analysis, of cardiovascular hospitalizations at 2 years</description>
        <time_frame>2 years</time_frame>
        <population>Analysis was intention to treat therefore all randomized patients were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O2">
            <title>MVP Only</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O3">
            <title>DDDRP</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cardiovascular Hospitalizations at 2 Years</title>
          <description>Incidence, estimated via Kaplan Meier survival analysis, of cardiovascular hospitalizations at 2 years</description>
          <population>Analysis was intention to treat therefore all randomized patients were analysed</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="13.3" upper_limit="21.2"/>
                    <measurement group_id="O2" value="13.7" lower_limit="10.5" upper_limit="17.7"/>
                    <measurement group_id="O3" value="15.2" lower_limit="11.8" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Burden of Composite Clinical Endpoint</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Symptoms</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Medications</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percentage of Ventricular Pacing</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Death</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Hospitalization</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Fibrillation Burden</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistent Atrial Fibrillation (AF)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Atrioventricular (AV) Block and Pacemaker Dependency</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors of Stroke, Transient Ischemic Attack (TIA) and Arterial Embolism</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiogram Data About Left Ventricular Fractional Shortening and Ejection Fraction and Left Atrium Dilatation</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in All the Patients With MVP ON Between Patients With Optimized AV-delay and Patients Without Optimized AV-delay</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Development of the Composite Endpoint Between All Randomized Subjects in the Three Arms in Subgroups of Patients</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency, Type, and Associated Cost of Health Care Utilization and Utility</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 Years</title>
        <description>The outcome measurement is the 2 years incidence, calculated by Kaplan Meier survival analysis, of the composite endpoint composed by death for any cause, cardiovascular hospitalization or permanent AF.</description>
        <time_frame>2 years</time_frame>
        <population>Analysis was intention to treat therefore all randomized patients were considered in the analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O2">
            <title>MVP Only</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
          <group group_id="O3">
            <title>DDDRP</title>
            <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 Years</title>
          <description>The outcome measurement is the 2 years incidence, calculated by Kaplan Meier survival analysis, of the composite endpoint composed by death for any cause, cardiovascular hospitalization or permanent AF.</description>
          <population>Analysis was intention to treat therefore all randomized patients were considered in the analyses</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="23.7" upper_limit="32.9"/>
                    <measurement group_id="O2" value="23.1" lower_limit="19.1" upper_limit="27.8"/>
                    <measurement group_id="O3" value="21.5" lower_limit="17.6" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>PM programming according to actual clinical practice
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="E2">
          <title>MVP Only</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
        <group group_id="E3">
          <title>DDDRP</title>
          <description>PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
Pacemaker Medtronic EnRhythm: Pacemaker specific programming</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="385"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="398"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Coagulation problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Cornary Syndrome/Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="385"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="398"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Atrial Arrhythmia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="42" subjects_at_risk="385"/>
                <counts group_id="E2" events="71" subjects_affected="50" subjects_at_risk="398"/>
                <counts group_id="E3" events="42" subjects_affected="38" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>AV conduction disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="385"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>General cardiovascular disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="385"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="398"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Sympthoms of chest pain, angina, palpitation, dyspnea on exertion or cardiopalmo</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="385"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia or Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose metabolism disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="385"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death for non cardiac reason</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="385"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Death for unknown causes</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="385"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="398"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hemorrage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="385"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="398"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other general disorders</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="385"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="398"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladdert disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and infestations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Consequences of drugs administration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="385"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="398"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pacemaker/Lead related complications</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Ureteral catheter dysfunction or dislodgement</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Enteroscopy, colonoscopy or video capsule endoscopy procedure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoloskeletal disease</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="385"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="398"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="385"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="398"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostate disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Renal or urinary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="398"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="398"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="385"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Symptoms of dyspnea, shortness of breath, fatigue, cough and or tachypnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ablation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass Graft</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other cardiac surgical interventions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other surgical interventions</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="385"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="398"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pacemaker replacement, explant or repositioning</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="385"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="398"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Stent implantation/Angiography</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="385"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other cerebrovascular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Other vascular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Clinical Research Manager</name_or_title>
      <organization>Medtronic</organization>
      <phone>0039-0632814225</phone>
      <email>andrea.grammatico@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

